MIRA
INFORM REPORT
|
Report Date : |
21.07.2014 |
IDENTIFICATION DETAILS
|
Name : |
RESEARCH PHARMACEUTICAL LIMITED |
|
|
|
|
Registered Office : |
Building 16 I Oriental International Science &
Technical Bldg., |
|
|
|
|
Country : |
|
|
|
|
|
Date of Incorporation : |
10.03.2005 |
|
|
|
|
Com. Reg. No.: |
310115500100172 |
|
|
|
|
Legal Form : |
Representative Office |
|
|
|
|
Line of Business : |
Subject is engaged in trade liaison for importing
and exporting pharmaceutical raw materials, pesticide and plant extracts. |
|
|
|
|
No. of Employees : |
08 |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
Payment Behaviour : |
Unknown |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2014
|
Country Name |
Previous Rating (31.12.2013) |
Current Rating (31.03.2014) |
|
China |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderately Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderately High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
CHINA - ECONOMIC OVERVIEW
Since the late 1970s China has
moved from a closed, centrally planned system to a more market-oriented one
that plays a major global role - in 2010 China became the world's largest
exporter. Reforms began with the phasing out of collectivized agriculture, and
expanded to include the gradual liberalization of prices, fiscal
decentralization, increased autonomy for state enterprises, growth of the
private sector, development of stock markets and a modern banking system, and
opening to foreign trade and investment. China has implemented reforms in a
gradualist fashion. In recent years, China has renewed its support for
state-owned enterprises in sectors considered important to "economic
security," explicitly looking to foster globally competitive industries.
After keeping its currency tightly linked to the US dollar for years, in July
2005 China moved to an exchange rate system that references a basket of
currencies. From mid 2005 to late 2008 cumulative appreciation of the renminbi
against the US dollar was more than 20%, but the exchange rate remained
virtually pegged to the dollar from the onset of the global financial crisis
until June 2010, when Beijing allowed resumption of a gradual appreciation and
expanded the daily trading band within which the RMB is permitted to fluctuate.
The restructuring of the economy and resulting efficiency gains have
contributed to a more than tenfold increase in GDP since 1978. Measured on a
purchasing power parity (PPP) basis that adjusts for price differences, China
in 2013 stood as the second-largest economy in the world after the US, having
surpassed Japan in 2001. The dollar values of China's agricultural and
industrial output each exceed those of the US; China is second to the US in the
value of services it produces. Still, per capita income is below the world
average. The Chinese government faces numerous economic challenges, including:
(a) reducing its high domestic savings rate and correspondingly low domestic
consumption; (b) facilitating higher-wage job opportunities for the aspiring
middle class, including rural migrants and increasing numbers of college
graduates; (c) reducing corruption and other economic crimes; and (d)
containing environmental damage and social strife related to the economy's
rapid transformation. Economic development has progressed further in coastal
provinces than in the interior, and by 2011 more than 250 million migrant
workers and their dependents had relocated to urban areas to find work. One
consequence of population control policy is that China is now one of the most rapidly
aging countries in the world. Deterioration in the environment - notably air
pollution, soil erosion, and the steady fall of the water table, especially in
the North - is another long-term problem. China continues to lose arable land
because of erosion and economic development. The Chinese government is seeking
to add energy production capacity from sources other than coal and oil,
focusing on nuclear and alternative energy development. Several factors are
converging to slow China's growth, including debt overhang from its
credit-fueled stimulus program, industrial overcapacity, inefficient allocation
of capital by state-owned banks, and the slow recovery of China's trading
partners. The government's 12th Five-Year Plan, adopted in March 2011 and reiterated
at the Communist Party's "Third Plenum" meeting in November 2013,
emphasizes continued economic reforms and the need to increase domestic
consumption in order to make the economy less dependent in the future on fixed
investments, exports, and heavy industry. However, China has made only marginal
progress toward these rebalancing goals. The new government of President XI
Jinping has signaled a greater willingness to undertake reforms that focus on
China's long-term economic health, including giving the market a more decisive
role in allocating resources.
|
Source
: CIA |
Company Name & Address
RESEARCH
PHARMACEUTICAL LIMITED SHANGHAI OFFICE
BUILDING 16 I ORIENTAL INTERNATIONAL SCIENCE & TECHNICAL BLDG.,
NO. 58 XIANGCHENG ROAD, PUDONG NEW ZONE, SHANGHAI 200122 PR CHINA
TEL: 86 (0) 20-68406232
FAX: 86 (0) 20-68406233
EXECUTIVE SUMMARY
Date of Registration : march 10, 2005
REGISTRATION NO. : 310115500100172
LEGAL FORM : REPRESENTATIVE OFFICE
CHIEF EXECUTIVE : LI
MEIFEN (Chief Representative)
REGISTERED CAPITAL : n/a
staff : 8
BUSINESS CATEGORY : liasion service
Revenue
n/a
EQUITIES :
n/a
WEBSITE : n/a
E-MAIL :
n/a
PAYMENT : not yet be determined
MARKET CONDITION : fair
FINANCIAL CONDITION : n/a
OPERATIONAL TREND : ORDINARY
GENERAL REPUTATION : AVERAGE
EXCHANGE RATE : CNY 6.20 = USD
1
ADOPTED
ABBREVIATIONS (AS FOLLOWS)
SC - Subject Company
(the company inquired by you)
N/A – Not available
CNY – China Yuan Ren
Min Bi
OPERATIONAL TREND & GENERAL
REPUTATION
This section aims at indicating the relative positions of SC in respect
of its operational trend & general reputation
Operational Trend:- General
Reputation:-
Upward Excellent
Steady Good
Fairly Steady Fairly
Good
Ordinary Average
Fair Fair
Stagnant Detrimental
Downward Not
known
Not known Not
yet be determined
Not yet be determined
LEGAL
STATUS & HISTORY
SC was established as a representative office of PRC with State
Administration of Industry & Commerce (SAIC) under registration No.:
310115500100172 on March 10, 2005.
SC’s Organization Code Certificate
No.: 77244022-5
Registration Change Record:-
|
Date |
Change of Contents |
Before the change |
After the change |
|
-- |
Registration No. |
14612 |
310115500100172 |
Current Co search indicates SC’s parent company & chief
executives are as follows:-
|
Name of Parent Company |
|
Research Pharmaceutical Limited (Hong Kong) |
SC’s Chief Executives:-
|
Position |
Name |
|
Chief Representative |
Li Meifen |
RECENT
DEVELOPMENT
No recent development was found during our checks at present.
PRARENT
COMPANY
Name
Research Pharmaceutical Limited (Hong Kong)
Research Pharmaceutical Limited is a comprehensive
company which focuses on medical-related businesses both home and abroad.
Web: www.researchpharmaceutical.com
*Registration*
---------------
CR No.: 0712318
Date of Registration: April 12, 2000
Legal Form: Private
Status: Live
Registered Address: 2706 Natwest Tower, Times Square, 1 Matheson Street,
Causeway Bay, Hong Kong
*Directors*
-------------
Jairo Alfonso Escobar Ramirez
Passport No.: CC 16627602
Cesar Orrego Echeverry
Passport No.: CC-16764635
Susana Helena Ortega Peterson
Passport No.: CC31281137
MANAGEMENT
Li Meifen, Chief Representative
----------------------------------------------------
Gender: F
Qualification: University
Working experience (s):
At present, working in SC as chief representative
BUSINESS
OPERATION
SC’s registered business scope includes engaged in
non-profit business activities related with its parent company
SC is mainly engaged in trade liaison for importing
and exporting pharmaceutical raw materials, pesticide and plant extracts.
The
products mainly include:
Active Pharmaceutical Ingredients (API)
Excipients
Pharmaceutical Packaging
Natural Products
Staff
& Office:
--------------------------
SC is known to have approx. 8 staff at present.
SC rents an area as its operating office of approx. 127 sq.
meters at the heading address.
RELATED
COMPANY
SC is not known to have any subsidiary at present.
PAYMENT
Overall payment appraisal: ( ) Excellent ( ) Good ( ) Average ( ) Fair ( ) Poor (X) Not yet be determined
The appraisal serves as a reference to reveal SC's payments habits and
ability to pay. It is based on the 3
weighed factors: Trade payment experience (through current enquiry with SC's
suppliers), our delinquent payment and our debt collection record concerning
SC.
Trade payment experience: Not available.
Delinquent payment record: None in our database.
Debt collection record: No overdue amount
owed by SC was placed to us for collection within the last 6 years.
BANKING
Basic Bank
Industrial and Commercial Bank of China Shanghai Lujiazui
Sub-branch
AC#: N/a
FINANCIALS
As a representative office, SC is not allowed to
engage in direct business. All its expenses are supposed to be provided by its
parent company. Therefore, its financials are not available.
CONCLUSIONS
SC is a representative office, which is not engaged in direct business. Taking into consideration of SC’s development history,
background and operation size, credit dealings
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.60.33 |
|
|
1 |
Rs.103.18 |
|
Euro |
1 |
Rs.81.58 |
INFORMATION DETAILS
|
Analysis Done by
: |
KAR |
|
|
|
|
Report Prepared
by : |
TPT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to
overcome financial difficulties seems comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.